Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
WASHINGTON Pharmaceutical company AstraZeneca told the Food and Drug Administration today that it would support legislation requiring drug manufacturers to submit all prescription drug ads to the regulatory agency for review prior to public dissemination. Under current FDA rules, submitting ads in advance is voluntary.
AstraZeneca made its comments to the FDA in written testimony during a two-day public hearing that the regulatory administration is holding on direct-to-consumer advertising of prescription drugs.
Drug companies spent more than $4 billion on DTC ads last year, per Nielsen Monitor-Plus.
“If
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in